The Efficacy and Safety of Multi-Kinase Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Beyond mitotane: next-generation therapeutic landscapes in adrenocortical carcinoma.Endocrine oncology (Bristol, England) · 2026
   Review
2. Diagnostic accuracy of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the differential diagnosis of adrenocortical carcinoma: a retrospective study.Translational andrology and urology · 2025
   Article
3. Marine-Derived Steroids for Cancer Treatment: Search for Potential Selective Glucocorticoid Receptor Agonists/Modulators (SEGRAMs).Marine drugs · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as